nach oben

BioDrugs

Erschienen in:

01.02.2013 | Correspondence

Immunogenicity Issues Related to Botulinum Toxins in Clinical Use Cannot Be Answered by Speculation About Product Characteristics

verfasst von: Andy Pickett

Erschienen in: BioDrugs | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Excerpt

The recent informative discussion by Professor Benecke [1] usefully deals with the subject of antibody formation to botulinum toxin (BoNT) during treatment. …

Benecke R. Clinical relevance of botulinum toxin immunogenicity. BioDrugs. 2012;26(2):e1–9.PubMedCrossRef

Shone C, Appleton N, Wilton-Smith P, Hambleton P, Modi N, Gatley S, et al. In vitro assays for botulinum toxin and antitoxins. Dev Biol Stand. 1986;64:141–5.PubMed

Johnson EA, Pellett S, Tepp W, Borodic GE. A neuronal cell-based assay for highly sensitive detection of pharmaceutical preparations of BONT/A and patient neutralizing serum antibodies [abstract]. Toxicon. 2008;51(Suppl. 1):14.CrossRef

Pickett A, Morte C, Pla F, Cedo M, Mirabet M, Peraire C, et al. Development of a multi-step approach for the detection of neutralising antibodies to botulinum toxin Type A [abstract]. Toxicon. 2008;51:18.

Schantz EJ, Johnson EA. Dose standardisation of botulinum toxin [letter]. Lancet. 1990;335(8686):421.PubMedCrossRef

Schantz EJ, Johnson EA. Properties and use of botulinum toxin and other microbial neurotoxins in medicine. Microbiol Rev. 1992;56(1):80–99.PubMed

Goodnough MC, Johnson EA. Stabilization of botulinum toxin type A during lyophilization. Appl Environ Microbiol. 1992;58(10):3426–8.PubMed

Borodic G, Johnson E, Goodnough M, Schantz E. Botulinum toxin therapy, immunologic resistance, and problems with available materials. Neurology. 1996;46(1):26–9.PubMedCrossRef

Eisele K-H, Fink K, Vey M, Taylor HV. Studies on the dissociation of botulinum neurotoxin type A complexes. Toxicon. 2011;57(4):555–65.PubMedCrossRef

10.

Friday D, Bigalke H, Frevert J. In vitro stability of botulinum toxin complex preparations at physiological pH and temperature. International conference on basic and therapeutic aspects of botulinum and tetanus toxins; 2002 Jun 8–12; Hannover, R20.

11.

Pickett A. Characteristics, properties and applications of botulinum toxins in therapeutic use today in the NHS. Br J Med Procure. 2012;4(1):16–23.

12.

Jost WH, Blumel J, Grafe S. Botulinum neurotoxin type A free of complexing proteins (XEOMIN) in focal dystonia. Drugs. 2007;67(5):669–83.PubMedCrossRef

13.

Bluemel J, Frevert J, Schwaier A. Comparative antigenicity of three preparations of botulinum neurotoxin type a in the rabbit. International conference on basic and therapeutic aspects of botulinum and tetanus toxins, (Toxins 2005); 2005 Jun 23–25; Denver, CO.

14.

Pickett A, Rosales RL. New trends in the science of botulinum toxin-A as applied in dystonia. Int J Neurosci. 2011;121 Suppl. 1(S1):22–34.

15.

Lange O, Bigalke H, Dengler R, Wegner F, deGroot M, Wohlfarth K. Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: much ado about nothing? Clin Neuropharmacol. 2009;32(4):213–8.PubMedCrossRef

16.

Naumann M, Carruthers A, Carruthers J, Aurora SK, Zafonte R, Abu-Shakra S, et al. Meta-analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX^®) across multiple indications. Mov Disord. 2010;25(13):2211–8.PubMedCrossRef

17.

Bakheit AM, Liptrot A, Newton R, Pickett AM. The effect of total cumulative dose, number of treatment cycles, interval between injections, and length of treatment on the frequency of occurrence of antibodies to botulinum toxin type A in the treatment of muscle spasticity. Int J Rehabil Res. 2012;35(1):36–9.PubMedCrossRef

Titel: Immunogenicity Issues Related to Botulinum Toxins in Clinical Use Cannot Be Answered by Speculation About Product Characteristics
verfasst von: Andy Pickett
Publikationsdatum: 01.02.2013
Verlag: Springer International Publishing AG
Erschienen in: BioDrugs / Ausgabe 1/2013
Print ISSN: 1173-8804
Elektronische ISSN: 1179-190X
DOI: https://doi.org/10.1007/s40259-012-0006-1

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2013

Targeting the B7 Family of Co-Stimulatory Molecules

Reduced-Antigen, Combined Diphtheria, Tetanus, and Acellular Pertussis Vaccine, Adsorbed (Boostrix®)

Vincristine Sulfate Liposome Injection

Selection of Potential Therapeutic Human Single-Chain Fv Antibodies against Cholecystokinin-B/Gastrin Receptor by Phage Display Technology

Bispecific Antibodies and Trispecific Immunocytokines for Targeting the Immune System Against Cancer

Targeting Focal Adhesion Kinase in Fibrotic Diseases